SCHEMBL20722392

SCHEMBL20722392

CC(C)(C)OC(=O)N[C@H]1CN(c2ccc3c(n2)CC[C@H](N)C3)C[C@H]1CF

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.38
PDE10A Q9Y233 3/20 0.35
EIF2AK4 Q9P2K8 1/20 0.35
HDAC4 P56524 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
RET P07949 2/20 0.33
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33
JAK3 P52333 2/20 0.33
BTK Q06187 2/20 0.33
DRD2 P14416 2/20 0.33
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
EGFR P00533 1/20 0.31
LCK P06239 1/20 0.31
SUV39H2 Q9H5I1 1/20 0.31
NPY5R Q15761 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20722631 1.00 MAP4K4 (0.38) MAP4K4PDE10AEIF2AK4HDAC4HDAC6
SCHEMBL30968484 1.00 MAP4K4 (0.38) MAP4K4PDE10AEIF2AK4HDAC4HDAC6
SCHEMBL28574715 1.00 MAP4K4 (0.38) MAP4K4PDE10AEIF2AK4HDAC4HDAC6
SCHEMBL30968531 1.00 MAP4K4 (0.38) MAP4K4PDE10AEIF2AK4HDAC4HDAC6
SCHEMBL30061949 1.00 MAP4K4 (0.38) MAP4K4PDE10AEIF2AK4HDAC4HDAC6
SCHEMBL20722733 0.90 MAP4K4 (0.37) MAP4K4PDE10AEIF2AK4RETCKS1B
SCHEMBL21684799 0.90 MAP4K4 (0.37) MAP4K4PDE10AEIF2AK4RETCKS1B
SCHEMBL31204568 0.90 MAP4K4 (0.37) MAP4K4PDE10AEIF2AK4RETCKS1B
SCHEMBL20722735 0.90 MAP4K4 (0.37) MAP4K4PDE10AEIF2AK4RETCKS1B
SCHEMBL30062024 0.90 MAP4K4 (0.37) MAP4K4PDE10AEIF2AK4RETCKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2024-12-10 US disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
EP-3833661-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Valo Early Discovery, Inc. (US) 2021-06-16 EP disclosed
CN-112867712-A Carboxamides as ubiquitin-specific protease inhibitors 瓦洛早期发现股份有限公司 2021-05-28 CN disclosed
EP-3665169-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2020-06-17 EP disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed
WO-2019032863-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 MAP4K4 1430/4885PDE10A 4340/4885EIF2AK4 2109/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 MAP4K4 1430/4885PDE10A 4340/4885EIF2AK4 2109/4885
US-12162888-B2 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 MAP4K4 1430/4885PDE10A 4340/4885EIF2AK4 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.